BioVector® CHLA-20 人神经母细胞瘤细胞系 / BioVector® CHLA-20 Human Neuroblastoma Cell Line

通用定义 / General Definition:

BioVector® CHLA-20 是一种源自人类神经母细胞瘤 (Neuroblastoma) 的细胞系。该细胞系与 CHLA-15 类似，同样建立于一名经历过密集化疗后复发的患儿。然而，CHLA-20 在分子表型上具有独特性：它通常被鉴定为 MYCN 非扩增型 (MYCN Non-amplified)，但可能存在其他遗传学改变（如 1p 缺失或 ALK 突变/扩增）。该细胞系是研究复发性、难治性神经母细胞瘤中非 MYCN 驱动因素的关键模型，常用于筛选新型化疗组合以及针对神经嵴起源肿瘤的靶向治疗研究。

BioVector® CHLA-20 is a human cell line derived from Neuroblastoma. Similar to CHLA-15, it was established from a pediatric patient at the time of disease relapse following heavy prior therapy. However, CHLA-20 is molecularly distinct, typically characterized as MYCN Non-amplified, though it may harbor other genetic aberrations such as 1p deletion or ALK mutations/amplification. This cell line serves as a critical model for studying non-MYCN drivers in recurrent, refractory neuroblastoma and is frequently used for screening novel drug combinations and targeted therapies against tumors of neural crest origin.

BioVector® CHLA-20 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® CHLA-20 人神经母细胞瘤细胞

• 组织来源： 转移灶（通常为外周血、骨髓或复发肿块）

• 分子特征：MYCN 单拷贝（非扩增）；可能携带 TP53 突变或 ALK 相关改变。

• 生长特性： 贴壁生长。

• 细胞形态： 上皮样或成纤维细胞样，具有明显的双极或多极神经突触样延伸。

2. 培养条件

• 基础培养基： BioVector® IMDM 或 DMEM/F-12 (1:1)。

• 血清添加： 10% - 20% BioVector® 优质胎牛血清 (FBS)。

• 补充因子： 为维持复发细胞的稳健生长，建议添加非必需氨基酸 (NEAA) 和 L-谷氨酰胺。

• 培养环境： 37 摄氏度，5% $CO_2$。

• 传代比例： 1:3 至 1:5；相比于 CHLA-15，CHLA-20 的倍增时间通常较短，生长更为迅速。

3. 细胞应用

• 比较肿瘤学： 与 MYCN 扩增型细胞对照，研究不同遗传背景下的耐药差异。

• ALK 抑制剂筛选： 若该亚型携带 ALK 突变，则是评估第二/三代 ALK 抑制剂效能的理想模型。

• 免疫疗法研究： 用于研究 GD2 抗体或其他神经母细胞瘤靶向免疫疗法的细胞毒性实验。

4. 注意事项

• 汇合度控制： 建议在细胞达到 80% 汇合时传代。过度生长会导致细胞堆叠成团，不仅增加消化难度，还可能导致表型漂移。

• 消化参数： 该细胞对胰酶较为敏感，建议使用预温的 0.25% Trypsin-EDTA 消化 2-3 分钟，待细胞变圆后立即加入含血清培养基终止。

English Datasheet

1. General Product Information

• Product Name: BioVector® CHLA-20 Human Neuroblastoma Cell Line

• Source: Metastatic site (typically peripheral blood, bone marrow, or relapsed mass)

• Molecular Profile:MYCN Non-amplified (Single copy); potentially carries TP53 mutations or ALK-related alterations.

• Growth Properties: Adherent.

• Morphology: Epithelial-like or fibroblast-like; cells often display distinct bipolar or multipolar neurite extensions.

2. Culture Conditions

• Basal Medium: BioVector® IMDM or DMEM/F-12 (1:1).

• Serum Supplement: 10% - 20% BioVector® Fetal Bovine Serum (FBS).

• Supplements: Supplementation with Non-Essential Amino Acids (NEAA) and L-Glutamine is recommended to support robust growth of this relapse-derived line.

• Incubation: 37°C, 5% $CO_2$.

• Subculturing: 1:3 to 1:5 ratio; CHLA-20 typically exhibits faster doubling times compared to CHLA-15.

3. Applications

• Comparative Oncology: Serving as a non-amplified control to study resistance mechanisms across different genetic backgrounds.

• ALK Inhibitor Screening: An ideal model for evaluating the efficacy of next-generation ALK inhibitors if the specific sub-clone harbors ALK aberrations.

• Immunotherapy Assays: Utilized in cytotoxicity experiments for GD2 antibodies or other neuroblastoma-targeted immunotherapies.

4. Key Usage Notes

• Confluency Management: Maintain cultures in the exponential growth phase; subculture at ~80% confluency to prevent excessive cell-to-cell stacking and subsequent phenotypic drift.

• Dissociation Sensitivity: These cells are relatively sensitive to enzymatic dissociation. Use pre-warmed 0.25% Trypsin-EDTA for 2-3 minutes and neutralize immediately once cells appear rounded to preserve viability.

注意 / Note: BioVector® CHLA-20 应在生物安全二级 (BSL-2) 条件下操作。由于其源自复发性样本，细胞可能表现出较高的代谢异质性，建议在进行药物筛选前进行 STR 鉴定以确保细胞系纯度。

BioVector® CHLA-20 should be handled under Biosafety Level 2 (BSL-2) conditions. Given its origin from a relapsed clinical specimen, the line may exhibit metabolic heterogeneity; BioVector® recommends STR profiling to verify cell line identity before major drug screening assays.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net